TARSUS PHARMACEUTICALS, INC.
Ownership & governance
Executives 5Directors 8Avg age 61Avg tenure 4.8y
BA
Bobak Azamian
Chief Executive Officer
Age 48Since 2018-08-31Profile →
+12
Executives5
BA
Bobak Azamian→
Chief Executive Officer
Age 48Since 2018-08-31
JF
Jeffrey Farrow→
Director of Finance/CFO
Age 64Since 2023-04-23
EY
Elizabeth Yeu-Lin→
Chief Tech/Sci/R&D Officer
Age 47Since 2024-11-03
SN
Sesha Neervannan→
Chief Operating Officer
Age 57Since 2020-07-15
DN
David Nakasone→
Investor Relations Contact
—Since 2021-08-31
Board of directors8
BA
Bobak Azamian→
Chairman
Age 48Since 2022-12-01
BC
Bhaskar Chaudhuri→
Director/Board Member
Age 71Since 2019-11-30
BL
Bill Link→
Director/Board Member
Age 80Since 2016-12-31
WY
Wendy Yarno→
Director/Board Member
Age 71Since 2020-11-18
AG
Andrew Goldberg→
Director/Board Member
Age 44Since 2020-07-31
SM
Scott Morrison→
Director/Board Member
Age 68Since 2022-10-05
KG
Katherine Goodrich→
Director/Board Member
Age 57Since 2024-11-12
DP
David Pyott→
Director/Board Member
Age 72Since 2026-02-17
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Deep Track Capital LP | 8.367 % | 3,600,000 |
| RTW Investments LP | 7.777 % | 3,346,025 |
| BlackRock Advisors LLC | 7.775 % | 3,345,198 |
| Paradigm BioCapital Advisors LP | 5.955 % | 2,562,154 |
| Janus Henderson Investors US LLC | 5.231 % | 2,250,446 |
Catalog · 2026-07-09
Registry officers13
| Name | Role | Since | Shares |
|---|---|---|---|
| Bobak Azamian | Chairman | 2022-12-01 | - |
| Bobak Azamian | Chief Executive Officer | 2018-08-31 | - |
| Elizabeth Yeu-Lin | Chief Tech/Sci/R&D Officer | 2024-11-03 | - |
| Jeffrey Farrow | Director of Finance/CFO | 2023-04-23 | - |
| Sesha Neervannan | Chief Operating Officer | 2020-07-15 | - |
| Andrew Goldberg | Director/Board Member | 2020-07-31 | - |
| Bhaskar Chaudhuri | Director/Board Member | 2019-11-30 | - |
| Bill Link | Director/Board Member | 2016-12-31 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 99.8Range 84–116Analysts 10
84Mean 99.8116
- Strong buy 1
- Buy 9
Broker actions40 of 54
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Jefferies | Maintained | Buy | 105 | 2026-09-08 |
| Oppenheimer | Maintained | Outperform | 100 | 2026-08-12 |
| Mizuho | Maintained | Outperform | 98 | 2026-07-31 |
| Guggenheim | Maintained | Buy | 89 | 2026-07-21 |
| HC Wainwright & Co. | Reiterated | Buy | 88 | 2026-07-09 |
| HC Wainwright & Co. | Reiterated | Buy | 88 | 2026-05-04 |
| Oppenheimer | Maintained | Outperform | 105 | 2026-02-25 |
| Guggenheim | Maintained | Buy | 90 | 2026-02-25 |
| Barclays | Initiated | Overweight | 100 | 2025-12-09 |
| Mizuho | Initiated | Outperform | 100 | 2025-11-20 |
| Guggenheim | Maintained | Buy | 87 | 2025-11-05 |
| HC Wainwright & Co. | Maintained | Buy | 88 | 2025-10-20 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.